eur op eanexhibitionofcreati vityandinnovation - Europe Direct Iasi
eur op eanexhibitionofcreati vityandinnovation - Europe Direct Iasi
eur op eanexhibitionofcreati vityandinnovation - Europe Direct Iasi
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
EUROINVENT 2013<br />
41.1.<br />
Title<br />
Authors<br />
Biotehnos S.A.<br />
The devel<strong>op</strong>ment of phytotherapic products with action<br />
against cutaneous inflammatory disturbances – a genuine<br />
application of the new biotechnological infrastructure of<br />
R&D from Biotehnos<br />
Olariu Laura Zglimbea Lenuta, Dumitriu Brandusa, Ene<br />
Manuela Diana, Nita Roxana Andreea, Dinca Gabriela<br />
Biotehnos S.A.<br />
Institution<br />
Patent no. A00618/ 23.08.2012, 922/ 22.08.2012<br />
Description<br />
Class<br />
Biotehnos - a Romanian company - has managed to devel<strong>op</strong> in<br />
three years a R&D infrastructure at international standards, thus<br />
implementing its own original concept of interrelationships:<br />
Research - Application - Capitalization. As a consequence of<br />
Biotehnos R&D infrastructure devel<strong>op</strong>ment (acquisitions of LC-<br />
MS, RT-PCR, analysing system for transdermal preparations,<br />
irradiation system for bioanalysis, among others) there were<br />
obtained several phytherapic products with cumulative dermal<br />
restructuring and antiinflammatory actions for treatment of<br />
various path<strong>op</strong>hysiological manifestations such as cutaneous<br />
tissue cellulitis, peripheral edema, dark circles.<br />
Original combination of bioactive components from various<br />
plants meant for these phytherapic products’ devel<strong>op</strong>ment<br />
determined the integration of the obtained results into a patent<br />
that brings in the pooling of stimulating dermal restructuring<br />
actions given by the cellular and protein turn-over and the<br />
adhesion process cell - extracellular matrix, the sunscreen<br />
effect by inducing cellular protection against ap<strong>op</strong>tosis, together<br />
with antioxidant, anti-inflammatory and anti-angiogenic effects<br />
against UV radiation, anti-vascular inflammation through the<br />
inhibition of pro-inflammatory cytokines IL6 and IL8 and<br />
monocyte - endothelium adhesion molecules overexpression<br />
(ICAM and VCAM) and, finally, the anti-vascular<br />
permeability through VEGF factor inhibition. All these effects<br />
are evidenced by specific tests for each one in part.<br />
The input in Biotehnos’ biotechnology research infrastructure<br />
was made on the basis of the project POS 275 / CNRS 6009<br />
CTR 74/2009, while the patent devel<strong>op</strong>ment was made in the<br />
frame of the project POS 383 / CNRS 6009 CTR 107/2010.<br />
4. Medicine - Health Care - Cosmetics<br />
NATIONAL<br />
216